Variables | Univariate Model | Adjusted Model | ||
---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | |
Female | 2.31 (0.51–10.38) | 0.276 |  | |
Age at SLE diagnosis (yrs) | 0.97 (0.82–1.14) | 0.692 | ||
Clinical manifestations (at SLE diagnosis) | ||||
 Malar rash | 0.90 (0.37–2.22) | 0.821 | ||
 Discoid rash | 0.15 (0.02–1.09) | 0.061 | ||
 Photosensitivity | 0.95 (0.34–2.65) | 0.926 | ||
 Oral ulcer | 1.64 (0.66–4.08) | 0.290 | ||
 Arthritis | 1.52 (0.58–3.98) | 0.393 | ||
 Serositis | 1.98 (0.71–5.50) | 0.193 | ||
 CNS involvement | 1.61 (0.21–12.44) | 0.651 | ||
 Haematology | 1.12 (0.43–2.93) | 0.818 | ||
 Hepatitis | 0.56 (0.15–2.06) | 0.377 | ||
 Leukopeniaa | 0.91 (0.25–3.45) | 0.930 | ||
 Lymphopeniab | 1.67 (0.54–5.14) | 0.373 | ||
 Thrombocytopeniac | 1.26 (0.35–4.60) | 0.726 | ||
During the period of follow up | ||||
 dRVVT ever positive | 1.30 (0.48–3.55) | 0.604 | ||
 Average (anti-dsDNA antibody/100) (IU/ml) | 1.37 (1.16–1.63) |  < 0.001 | 1.289 (1.06–1.57) | 0.013 |
 Average C3 (mg/dL) | 0.95 (0.92–0.98) |  < 0.001 | 0.971 (0.93–1.01) | 0.145 |
 Average C4 (mg/dL) | 0.89 (0.80–0.99) | 0.029 | 0.972 (0.86–1.10) | 0.663 |
 Average ESR (mm/hr) | 1.02 (1.01–1.04) | 0.011 | 1.022 (1.00–1.04) | 0.045 |
 Accumulated steroid dose (mg/day) | 1.15 (1.05–1.26) | 0.004 | 1.001 (0.88–1.14) | 0.985 |
 HCQ | 1.0 (0–911,390.05) | 1 |  | |
 CsA | 1.33 (0.53–3.34) | 0.545 | ||
 MTX | 2.27 (0.75–6.88) | 0.147 | ||
 MMF | 1.06 (0.43–2.61) | 0.901 | ||
 AZA | 0.94 (0.39–2.27) | 0.891 |